Her main research concerns Pathology, Carcinoma, Immunohistochemistry, Stromal cell and Internal medicine. Her Ovary research extends to Pathology, which is thematically connected. Her Carcinoma research is multidisciplinary, incorporating elements of Transitional cell carcinoma, Ovarian carcinoma, Metastasis, Renal cell carcinoma and Adenocarcinoma.
In the subject of general Immunohistochemistry, her work in Immunostaining is often linked to GATA3, thereby combining diverse domains of study. Her studies deal with areas such as CD34, Stroma and Atypia as well as Stromal cell. Her Internal medicine research includes elements of Gastroenterology, Endocrinology and Oncology.
Her primary areas of study are Pathology, Internal medicine, Carcinoma, Immunohistochemistry and Oncology. The study incorporates disciplines such as Uterus and Ovary in addition to Pathology. In most of her Internal medicine studies, her work intersects topics such as Gastroenterology.
In her work, Serous carcinoma is strongly intertwined with Serous fluid, which is a subfield of Carcinoma. Her study connects Staining and Immunohistochemistry. Her International Prognostic Scoring System study in the realm of Myelodysplastic syndromes interacts with subjects such as In patient.
Esther Oliva spends much of her time researching Pathology, Internal medicine, Carcinoma, Myelodysplastic syndromes and Oncology. The Pathology study combines topics in areas such as Endometrial cancer and General surgery. Her Internal medicine research focuses on Gastroenterology and how it relates to Tumor size.
The various areas that she examines in her Carcinoma study include Endometrial Carcinomas, Lymphovascular, Stromal Invasion and Adenosquamous carcinoma. Her Myelodysplastic syndromes research is multidisciplinary, relying on both Lower risk, Anemia and Intensive care medicine. Her specific area of interest is Oncology, where Esther Oliva studies Grading.
Esther Oliva mainly focuses on Pathology, Carcinoma, Endometrial cancer, Internal medicine and Oncology. Esther Oliva integrates many fields, such as Pathology and PAX8, in her works. Her work deals with themes such as Biopsy, Disease, General surgery and Adenosquamous carcinoma, which intersect with Carcinoma.
Her Endometrial cancer research is multidisciplinary, incorporating perspectives in Hormone therapy, Serous carcinoma, Family medicine and Carcinosarcoma. The concepts of her Oncology study are interwoven with issues in Ovarian carcinoma, Incidence and Lynch syndrome, DNA mismatch repair. Her study explores the link between Differential diagnosis and topics such as Mitotic index that cross with problems in Immunohistochemistry.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma
Geert J.L.H. van Leenders;Theodorus H. van der Kwast;David J. Grignon;Andrew J. Evans.
The American Journal of Surgical Pathology (2005)
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Silvia de Sanjose;Wim G.V. Quint;Laia Alemany;Daan T. Geraets.
Lancet Oncology (2010)
Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases
Robert H. Young;Esther Oliva;Robert E. Scully.
The American Journal of Surgical Pathology (1994)
An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies.
Esther Oliva;Robert H Young;Mahul B Amin;Philip B Clement.
The American Journal of Surgical Pathology (2002)
Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma.
C. Blake Gilks;Esther Oliva;Robert A. Soslow.
The American Journal of Surgical Pathology (2013)
Endometrial stromal tumors: an update on a group of tumors with a protean phenotype.
Esther Oliva;Philip B. Clement;Robert H. Young.
Advances in Anatomic Pathology (2000)
Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.
Douglas C Parker;Andrew L Folpe;Julie Bell;Esther Oliva.
The American Journal of Surgical Pathology (2003)
Micro-RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcoma
María Ángeles Castilla;Gema Moreno-Bueno;Laura Romero-Pérez;Koen Van De Vijver.
The Journal of Pathology (2011)
Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene
Chad A Hall;Runsheng Wang;Jiangyong Miao;Esther Oliva.
Cancer Research (2010)
The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor.
Cheng-Han Lee;Adrian Mariño-Enriquez;Wenbin Ou;Meijun Zhu.
The American Journal of Surgical Pathology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: